{"title":"开发社区获得性肺炎与潜在肺癌的预测评分:一项回顾性病例对照研究。","authors":"João Barbosa-Martins , Joana Mendonça , Nuno Carvalho , Carolina Carvalho , Gustavo Soutinho , Helena Sarmento , Camila Coutinho , Jorge Cotter","doi":"10.1016/j.rmed.2024.107675","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><p>A pneumonic infiltrate might hide an occult lung cancer (LC). This awareness depends on each clinician personal experience, turning definitive LC diagnosis challenging and possibly delayed. In this study we aimed to develop a clinical score to better identify those cases.</p></div><div><h3>Materials and methods</h3><p>We conducted a retrospective case–control study, including previously undiagnosed LC patients admitted in our institution, with a presumptive suspicious of community acquired pneumonia (CAP). Cases were compared with random CAP inpatient controls, using a matched 2:1 ratio. Demographic, clinical, and laboratorial variables were assessed for a possible association with the presence of a CAP with underlying LC (CAP–uLC).</p></div><div><h3>Results</h3><p>Among 535 hospitalized LC patients, 43 cases had a presentation compatible with CAP and were compared with 86 CAP controls. A scoring system was built using 6 independent variables, which positively correlated with CAP–uLC: smoking history (OR: 8.3 [1.9–36.2]; p = 0.005); absence of fever (6.5 [2.0–21.5]; p = 0.002); sputum with blood (5.9 [1.2–29.9]; p = 0.033); platelet count ≥ 232x10<sup>3</sup>/μL (5.8 [1.6–20.6]; p = 0.006); putative alternative diagnosis than CAP (4.6 [1.5–14.7]; p = 0.009); and duration of symptoms ≥ 10 days (3.7 [1.1–13.0]; p = 0.037). Our score presented an AUC of 0.910 (95 % CI, 0.852–0.967; p < 0.001), a sensitivity of 88.1 % and specificity of 84.7 %, in predicting the risk of presenting a CAP–uLC, when set to a cutoff of 18.</p></div><div><h3>Conclusion</h3><p>We propose a novel risk score aimed to aid clinicians identifying patients with CAP–uLC in the acute setting, possibly prompting early LC diagnosis.</p></div>","PeriodicalId":21057,"journal":{"name":"Respiratory medicine","volume":null,"pages":null},"PeriodicalIF":3.5000,"publicationDate":"2024-05-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Development of a predictive score to discriminate community acquired pneumonia with underlying lung cancer: A retrospective case – control study\",\"authors\":\"João Barbosa-Martins , Joana Mendonça , Nuno Carvalho , Carolina Carvalho , Gustavo Soutinho , Helena Sarmento , Camila Coutinho , Jorge Cotter\",\"doi\":\"10.1016/j.rmed.2024.107675\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Background</h3><p>A pneumonic infiltrate might hide an occult lung cancer (LC). This awareness depends on each clinician personal experience, turning definitive LC diagnosis challenging and possibly delayed. In this study we aimed to develop a clinical score to better identify those cases.</p></div><div><h3>Materials and methods</h3><p>We conducted a retrospective case–control study, including previously undiagnosed LC patients admitted in our institution, with a presumptive suspicious of community acquired pneumonia (CAP). Cases were compared with random CAP inpatient controls, using a matched 2:1 ratio. Demographic, clinical, and laboratorial variables were assessed for a possible association with the presence of a CAP with underlying LC (CAP–uLC).</p></div><div><h3>Results</h3><p>Among 535 hospitalized LC patients, 43 cases had a presentation compatible with CAP and were compared with 86 CAP controls. A scoring system was built using 6 independent variables, which positively correlated with CAP–uLC: smoking history (OR: 8.3 [1.9–36.2]; p = 0.005); absence of fever (6.5 [2.0–21.5]; p = 0.002); sputum with blood (5.9 [1.2–29.9]; p = 0.033); platelet count ≥ 232x10<sup>3</sup>/μL (5.8 [1.6–20.6]; p = 0.006); putative alternative diagnosis than CAP (4.6 [1.5–14.7]; p = 0.009); and duration of symptoms ≥ 10 days (3.7 [1.1–13.0]; p = 0.037). Our score presented an AUC of 0.910 (95 % CI, 0.852–0.967; p < 0.001), a sensitivity of 88.1 % and specificity of 84.7 %, in predicting the risk of presenting a CAP–uLC, when set to a cutoff of 18.</p></div><div><h3>Conclusion</h3><p>We propose a novel risk score aimed to aid clinicians identifying patients with CAP–uLC in the acute setting, possibly prompting early LC diagnosis.</p></div>\",\"PeriodicalId\":21057,\"journal\":{\"name\":\"Respiratory medicine\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":3.5000,\"publicationDate\":\"2024-05-21\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Respiratory medicine\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0954611124001495\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"CARDIAC & CARDIOVASCULAR SYSTEMS\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Respiratory medicine","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0954611124001495","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0
摘要
背景:肺部浸润可能隐藏着隐匿性肺癌(LC)。这种认识取决于每位临床医生的个人经验,因此明确的肺癌诊断具有挑战性,甚至可能被延迟。在本研究中,我们旨在开发一种临床评分方法,以更好地识别这些病例:我们开展了一项回顾性病例对照研究,研究对象包括我院收治的既往未确诊的 LC 患者,他们被推测为社区获得性肺炎(CAP)的疑似患者。病例与随机 CAP 住院病人对照组按 2:1 的配对比例进行比较。对人口统计学、临床和实验室变量进行了评估,以确定是否存在与潜在 LC(CAP-uLC)相关的 CAP:结果:在 535 名住院的 LC 患者中,有 43 例与 CAP 表现相符,并与 86 例 CAP 对照组进行了比较。结果: 在 535 名住院的 LC 患者中,有 43 例患者的表现与 CAP 相符,并与 86 例 CAP 对照组进行了比较。利用 6 个独立变量建立了一个评分系统,这些变量与 CAP-uLC 呈正相关:吸烟史(OR:8.3 [1.9-36.2];P=0.005);无发热(6.5 [2.0-21.5];P=0.002);痰中带血(5.9[1.2-29.9];P=0.033);血小板计数≥232x103/uL(5.8[1.6-20.6];P=0.006);CAP以外的其他诊断(4.6[1.5-14.7];P=0.009);症状持续时间≥10天(3.7[1.1-13.0];P=0.037)。我们的评分的AUC为0.910(95% CI,0.852-0.967;p结论:我们提出了一种新的风险评分方法,旨在帮助临床医生在急性期识别 CAP-uLC 患者,从而可能促使早期 LC 诊断。
Development of a predictive score to discriminate community acquired pneumonia with underlying lung cancer: A retrospective case – control study
Background
A pneumonic infiltrate might hide an occult lung cancer (LC). This awareness depends on each clinician personal experience, turning definitive LC diagnosis challenging and possibly delayed. In this study we aimed to develop a clinical score to better identify those cases.
Materials and methods
We conducted a retrospective case–control study, including previously undiagnosed LC patients admitted in our institution, with a presumptive suspicious of community acquired pneumonia (CAP). Cases were compared with random CAP inpatient controls, using a matched 2:1 ratio. Demographic, clinical, and laboratorial variables were assessed for a possible association with the presence of a CAP with underlying LC (CAP–uLC).
Results
Among 535 hospitalized LC patients, 43 cases had a presentation compatible with CAP and were compared with 86 CAP controls. A scoring system was built using 6 independent variables, which positively correlated with CAP–uLC: smoking history (OR: 8.3 [1.9–36.2]; p = 0.005); absence of fever (6.5 [2.0–21.5]; p = 0.002); sputum with blood (5.9 [1.2–29.9]; p = 0.033); platelet count ≥ 232x103/μL (5.8 [1.6–20.6]; p = 0.006); putative alternative diagnosis than CAP (4.6 [1.5–14.7]; p = 0.009); and duration of symptoms ≥ 10 days (3.7 [1.1–13.0]; p = 0.037). Our score presented an AUC of 0.910 (95 % CI, 0.852–0.967; p < 0.001), a sensitivity of 88.1 % and specificity of 84.7 %, in predicting the risk of presenting a CAP–uLC, when set to a cutoff of 18.
Conclusion
We propose a novel risk score aimed to aid clinicians identifying patients with CAP–uLC in the acute setting, possibly prompting early LC diagnosis.
期刊介绍:
Respiratory Medicine is an internationally-renowned journal devoted to the rapid publication of clinically-relevant respiratory medicine research. It combines cutting-edge original research with state-of-the-art reviews dealing with all aspects of respiratory diseases and therapeutic interventions. Topics include adult and paediatric medicine, epidemiology, immunology and cell biology, physiology, occupational disorders, and the role of allergens and pollutants.
Respiratory Medicine is increasingly the journal of choice for publication of phased trial work, commenting on effectiveness, dosage and methods of action.